Effect of FTY720 on the SET-PP2A Complex in Acute Myeloid Leukemia; SET Binding Drugs Have Antagonistic Activity

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 May 1

PMID 24781014

Citations 38

Authors

R Pippa

A Dominguez

D J Christensen

I Moreno-Miralles

M J Blanco-Prieto

M P Vitek

M D Odero

Affiliations

Soon will be listed here.

Citing Articles

Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer's Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy.

Sheng L, Bhalla R Neurochem Res. 2024; 49(9):2273-2302.

PMID: 38844706 PMC: 11310295. DOI: 10.1007/s11064-024-04178-w.

Altering phosphorylation in cancer through PP2A modifiers.

Johnson H, Narayan S, Sharma A Cancer Cell Int. 2024; 24(1):11.

PMID: 38184584 PMC: 10770906. DOI: 10.1186/s12935-023-03193-1.

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.

Di Mambro A, Arroyo-Berdugo Y, Fioretti T, Randles M, Cozzuto L, Rajeeve V Oncogene. 2023; 42(50):3670-3683.

PMID: 37891368 PMC: 10709139. DOI: 10.1038/s41388-023-02840-1.

Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases.

Yu H, Zaveri S, Sattar Z, Schaible M, Perez Gandara B, Uddin A Medicina (Kaunas). 2023; 59(9).

PMID: 37763671 PMC: 10535831. DOI: 10.3390/medicina59091552.

PP2A-Mediated GSK3β Dephosphorylation Is Required for Protocadherin-7-Dependent Regulation of Small GTPase RhoA in Osteoclasts.

Kim H, Takegahara N, Choi Y Cells. 2023; 12(15).

PMID: 37566044 PMC: 10417323. DOI: 10.3390/cells12151967.

References

Walker C, Oaks J, Santhanam R, Neviani P, Harb J, Ferenchak G . Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013; 122(17):3034-44. PMC: 3811176. DOI: 10.1182/blood-2013-04-495374. View

Saito S, Shimoyama T, Nagata K . Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun. 1999; 259(2):471-5. DOI: 10.1006/bbrc.1999.0790. View

Cristobal I, Garcia-Orti L, Cirauqui C, Alonso M, Calasanz M, Odero M . PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011; 25(4):606-14. DOI: 10.1038/leu.2010.294. View

Switzer C, Cheng R, Vitek T, Christensen D, Wink D, Vitek M . Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011; 30(22):2504-13. PMC: 3107340. DOI: 10.1038/onc.2010.622. View

Neviani P, Harb J, Oaks J, Santhanam R, Walker C, Ellis J . PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013; 123(10):4144-57. PMC: 3784537. DOI: 10.1172/JCI68951. View

Perrotti D, Neviani P . Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013; 14(6):e229-38. PMC: 3913484. DOI: 10.1016/S1470-2045(12)70558-2. View

Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez M, Calasanz M . Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2011; 97(4):543-50. PMC: 3347675. DOI: 10.3324/haematol.2011.050542. View

Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I . Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett. 2011; 585(17):2653-9. PMC: 3181127. DOI: 10.1016/j.febslet.2011.07.020. View

Neviani P, Santhanam R, Oaks J, Eiring A, Notari M, Blaser B . FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007; 117(9):2408-21. PMC: 1950458. DOI: 10.1172/JCI31095. View

10.

Saddoughi S, Gencer S, Peterson Y, Ward K, Mukhopadhyay A, Oaks J . Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2012; 5(1):105-21. PMC: 3569657. DOI: 10.1002/emmm.201201283. View

11.

Agarwal A, Mackenzie R, Pippa R, Eide C, Oddo J, Tyner J . Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res. 2014; 20(8):2092-103. PMC: 3989420. DOI: 10.1158/1078-0432.CCR-13-2575. View

12.

Oaks J, Santhanam R, Walker C, Roof S, Harb J, Ferenchak G . Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013; 122(11):1923-34. PMC: 3772499. DOI: 10.1182/blood-2013-03-492181. View

13.

Yu G, Yan T, Feng Y, Liu X, Xia Y, Luo H . Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging. 2013; 34(7):1748-58. DOI: 10.1016/j.neurobiolaging.2012.12.025. View

14.

Christensen D, Ohkubo N, Oddo J, Van Kanegan M, Neil J, Li F . Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol. 2011; 186(4):2535-42. DOI: 10.4049/jimmunol.1002847. View